HomeCompareGNHAY vs SBUX

GNHAY vs SBUX: Dividend Comparison 2026

GNHAY yields 5.29% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNHAY wins by $6.09M in total portfolio value
10 years
GNHAY
GNHAY
● Live price
5.29%
Share price
$38.39
Annual div
$2.03
5Y div CAGR
62.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.25M
Annual income
$4,849,407.89
Full GNHAY calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — GNHAY vs SBUX

📍 GNHAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNHAYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNHAY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNHAY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNHAY
Annual income on $10K today (after 15% tax)
$449.27/yr
After 10yr DRIP, annual income (after tax)
$4,121,996.71/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, GNHAY beats the other by $4,066,032.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNHAY + SBUX for your $10,000?

GNHAY: 50%SBUX: 50%
100% SBUX50/50100% GNHAY
Portfolio after 10yr
$3.20M
Annual income
$2,457,624.01/yr
Blended yield
76.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

GNHAY
No analyst data
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNHAY buys
0
SBUX buys
0
No recent congressional trades found for GNHAY or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNHAYSBUX
Forward yield5.29%2.75%
Annual dividend / share$2.03$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR62.6%48.3%
Portfolio after 10y$6.25M$157.5K
Annual income after 10y$4,849,407.89$65,840.13
Total dividends collected$6.10M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: GNHAY vs SBUX ($10,000, DRIP)

YearGNHAY PortfolioGNHAY Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,559$859.42$11,107$407.21+$452.00GNHAY
2$13,878$1,509.66$12,512$626.87+$1.4KGNHAY
3$17,604$2,754.33$14,366$978.69+$3.2KGNHAY
4$24,146$5,309.21$16,929$1,557.50+$7.2KGNHAY
5$36,902$11,066.02$20,658$2,543.80+$16.2KGNHAY
6$65,185$25,700.29$26,406$4,302.22+$38.8KGNHAY
7$138,737$68,988.48$35,877$7,622.00+$102.9KGNHAY
8$371,577$223,128.79$52,741$14,352.64+$318.8KGNHAY
9$1,305,722$908,134.35$85,676$29,243.03+$1.22MGNHAY
10$6,246,530$4,849,407.89$157,513$65,840.13+$6.09MGNHAY

GNHAY vs SBUX: Complete Analysis 2026

GNHAYStock

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

Full GNHAY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this GNHAY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNHAY vs SCHDGNHAY vs JEPIGNHAY vs OGNHAY vs KOGNHAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.